DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages


Chronic spontaneous urticaria

Author: Donna Bartlett, Medical Writer, Allori, Melbourne, Victoria, Australia. Adjunct A/Prof Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell/Maria McGivern. December 2018.

This article was supported by an educational grant from Novartis, distributors of Xolair™ in New Zealand and Australia. Sponsorship does not influence content.


What is urticaria?

Urticaria is a condition characterised by the presence of weals (hives) and angioedema.

  • A weal is a superficial red or pale skin swelling, usually surrounded by erythema, which can persist from a few minutes to 24 hours. Weals are generally very itchy, but can also cause a burning sensation.
  • Angioedema is swelling within the deeper dermal layers of the skin or mucous membranes. The swelling is usually skin coloured, but it can be erythematous. Angioedema can be asymptomatic, itchy, or cause burning pain. It can take up to 72 hours to resolve.

Weals are accompanied by angioedema in up to 40% of cases, but angioedema may occur on its own in some people.

Urticaria affects up to one in four people at some time in their lives and can be classified by duration, acute or chronic, and by cause, whether spontaneous or inducible. Two or more different subtypes of urticaria may co-exist in one person.

Acute urticaria is the daily or episodic occurrence of weals, angioedema, or both, for under 6 weeks. There are multiple possible causes, including infections or allergies, but it is often idiopathic.

Figure 1. Classification of urticaria

Adapted from Zuberbier T et al, 2018.

Spontaneous urticaria and angioedema

What is chronic urticaria?

Chronic urticaria is the daily or episodic occurrence of weals, angioedema, or both, for 6 weeks or more. Chronic urticaria can persist for 1–5 years, sometimes longer.

International guidelines for the classification, diagnosis, and management of chronic urticaria have recently been published based on a consensus from multiple national and international societies.

Chronic urticaria may be classified as either spontaneous or inducible, and both types may co-exist in one patient. This article is about chronic spontaneous urticaria. (See DermNet's page on Chronic inducible urticaria).

What is chronic spontaneous urticaria?

Chronic spontaneous urticaria refers to chronic urticaria that has no specific cause or trigger. Weals are present on most days of the week for 6 weeks or more.

Chronic spontaneous urticaria was previously referred to as chronic idiopathic urticaria. This term is no longer used as many cases have an autoimmune basis.

Who gets chronic urticaria?

Estimates of the incidence of chronic urticaria range from 0.05% to 2% of the population in the US, and up to 20% of the population in Thailand.

  • The lifetime prevalence of chronic urticaria is approximately 1.8%.
  • Chronic spontaneous urticaria occurs in 0.5–1% of the population at any point in time.
  • Two out of three cases of chronic urticaria are spontaneous, with its incidence peaking between 20 and 40 years of age.
  • Most studies have reported that women experience urticaria and chronic urticaria almost twice as often as men.
  • The incidence of urticaria in children has been reported at between 2% and 7% and the incidence of chronic urticaria in this age group is between 0.1% and 3%.
  • Chronic urticaria is more common in older children and adolescents.
  • Spontaneous urticaria is the most common subgroup of chronic urticaria in children.

What are the clinical features of chronic spontaneous urticaria?

Chronic spontaneous urticaria is characterised by the presence of weals and angioedema.

Weals can affect any site on the body and tend to be distributed widely.

  • Weals can be a few millimetres or several centimetres in diameter.
  • They can be coloured white or red, usually with a red flare.
  • Each weal may last a few minutes or several hours, and they may change shape before resolving.
  • Weals may be round or form rings, a map-like pattern, or giant patches.

Urticarial weals

See more images of urticaria and angioedema.

Angioedema is more often localised.

  • It commonly affects the face (presenting as swollen lips or eyelids), hands, feet, and genitalia.
  • It may involve the tongue, uvula, soft palate, and pharynx.


Chronic spontaneous urticaria is unpredictable and debilitating. The weals are more persistent in chronic spontaneous urticaria than in chronic inducible urticaria, but each tends to resolve or alter in shape within 24 hours. They may occur at certain times of the day.

Some patients with chronic spontaneous urticaria report associated systemic symptoms. These may include:

  • Headache and fatigue
  • Joint pain and swelling
  • Wheezing, flushing, and palpitations
  • Gastrointestinal symptoms.

How is the activity and control of urticaria assessed?

There are several validated systems to assess the activity and control of urticaria.

Disease activity in chronic spontaneous urticaria can be assessed with the 7-day Urticaria Activity Score (UAS7), a simple, validated scoring system based on the assessment of key urticaria signs and symptoms — weals and pruritus — that are documented by the patient. The daily weal and pruritus scores are added up for 7 days; the maximum score is 42.

The 7-day Urticaria Activity Score for assessment of disease activity
Score Weals Score Pruritus
0 None 0 None
1 Mild (< 20 weals/24 hours) 1 Mild (present but not annoying or troublesome)
2 Moderate (20–50 weals/24 hours) 2 Moderate (troublesome but does not interfere with normal daily activity or sleep)
3 Intense (> 50 weals/24 hours or large confluent area of weals) 3 Intense (severe pruritus that is sufficiently troublesome to interfere with normal daily activity or sleep)
The score for weals + the score for itch = daily score. Repeat daily for 7 days and add up the scores for UAS7. 

The Urticaria Control Test (UCT) is useful in the assessment of the patient’s disease status and is validated to determine the level of disease control in both chronic spontaneous urticaria and chronic inducible urticaria. The UCT has four items with a clear cut-off for ‘well controlled’ versus ‘poorly controlled’ disease, making it useful in routine clinical practice.

The Angioedema Activity Score (AAS) allows the patient to score each of five key factors relating to their experience of angioedema from 0 to 3 (giving a daily score of 0–15). Daily AAS can be summed to provide 7-day (AAS7), 4-week (AAS28), and 12-week (AAS84) scores.

Assessment of quality of life in chronic urticaria

Current international guidelines recommend validated instruments to assess the emotional impact of chronic urticaria and the effect on the patient’s quality of life, such as the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) and the Angioedema Quality of Life Questionnaire (AE-QoL).

What causes chronic spontaneous urticaria?

Urticaria is a mast cell-driven disease. Activated mast cells release histamine along with other mediators, such as platelet-activating factor and cytokines, resulting in sensory nerve activation, vasodilation, plasma extravasation, and recruitment of cells to the urticarial lesion. Many different molecules can activate mast cells in urticaria, but generally, these are not well defined.

By definition, chronic spontaneous urticaria has no known trigger. Causes include:

Chronic spontaneous urticaria may be due to a type I allergy in exceptionally rare cases.

There is a strong association between chronic spontaneous urticaria and other immune disorders, in particular, autoimmune thyroid disease. Thyroid autoantibodies are the most common laboratory abnormalities associated with chronic spontaneous urticaria, with most studies reporting elevated levels in 10% or more of affected patients. Thyroid dysfunction rates are also increased in people with chronic spontaneous urticaria, with hypothyroidism, and Hashimoto thyroiditis observed more commonly than hyperthyroidism and Graves disease.

The frequency of underlying causes varies in different studies of chronic spontaneous urticaria, reflecting regional differences in diet or the prevalence of infections.

What are the complications of chronic urticaria?

The burden of chronic spontaneous urticaria

Patients with chronic spontaneous urticaria may experience sleep deprivation, anxiety, depression, lack of energy, and social isolation. These can result in a significant deterioration in the patient's quality of life (see figure 2). Chronic spontaneous urticaria is unpredictable and can disrupt the patient’s normal daily activities.

Figure 2. Impact of chronic spontaneous urticaria on quality of life, sleep, and daily activities

Note: Higher score indicates greater impairment of quality of life.
Credit: Adapted from Maurer M, et al. Allergy 2017; 72: 2005–16.

How is chronic spontaneous urticaria diagnosed?

Chronic urticaria is diagnosed through the taking of a careful history and examination; this diagnosis is based on a history lasting over 6 weeks of daily or episodic weals that last less than 24 hours without the presence of physical trigger factors.

International guidelines provide a diagnostic algorithm for chronic urticaria (see figure 3). The diagnosis of chronic spontaneous urticaria relies on compiling a thorough history covering:

  • Time of onset of disease
  • The shape, size, frequency, and distribution of weals
  • Associated angioedema
  • Associated symptoms such as bone/joint pain, fever, and abdominal cramps
  • Personal and family history of weals and angioedema
  • Induction by physical agents or exercise
  • Occurrence in relation to daytime, weekends, menstrual cycle, holidays, and foreign travel
  • Occurrence with food or drugs (non-steroidal anti-inflammatory drugs [NSAIDs], angiotensin-converting enzyme [ACE] inhibitors)
  • Occurrence with infections or psychological stress
  • Previous or current allergies, infections, internal/autoimmune diseases, gastrointestinal problems, or other disorders
  • The patient's social and occupational history
  • Leisure activities
  • Prior therapy and response to treatment, including dosage and duration
  • Preceding diagnostic procedures and results.

The international guidelines recommend limiting investigations in most patients with chronic spontaneous urticaria to differential blood count and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Further diagnostic measures are based on patient history and examination, especially in patients with long-standing and uncontrolled disease.

Figure 3. Diagnostic algorithm for chronic urticaria

Credit: Adapted from Zuberbier T, et al. Allergy 2018.

Notes on diagnostic algorithm for chronic urticaria

  • Apart from ACE inhibitors, other renin inhibitors and sartans have also been reported to induce angioedema but much less frequently.
  • Patients should be asked for detailed family history and age at onset of disease.
  • Test for elevated inflammation markers (eg, CRP and ESR), test for paraproteinemia in adults, look for signs of neutrophil-rich infiltrates in skin biopsies, and perform gene mutation analysis for hereditary periodic fever syndromes (eg, cryopyrin-associated periodic syndromes) if strongly suspected.
  • Patients should be asked, “How long does each weal last?”
  • Test for complement C4, and C1-inhibitor levels and function; also test for C1q and C1-inhibitor antibodies if acquired and angioedema is suspected; and do gene mutation analysis if the former tests are unremarkable but the patient’s history suggests hereditary angioedema.
  • If there is no remission after 6 months of ACE-inhibitor discontinuation, test C1-inhibitor levels.
  • Does the biopsy of lesional skin show damage to the small vessels in the papillary and reticular dermis and fibrinoid deposits in perivascular and interstitial locations suggestive of urticarial vasculitis?
  • Patients should be asked, “Can you make your weals appear? Can you bring out your weals?”
  • In patients with a history suggestive of inducible urticaria, standardized provocation testing according to international consensus recommendation should be performed [16].
  • Acquired autoinflammatory syndromes include Schnitzler syndrome, systemic juvenile idiopathic arthritis, and adult-onset Stills disease; hereditary autoinflammatory syndrome include cryopyrin-associated periodic syndromes, such as familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease, more rarely hyper-IgD syndrome and tumour necrosis factor receptor associated periodic syndrome.
  • In some rare cases, recurrent angioedema is neither mast cell mediator-mediated nor bradykinin-mediated, and the underlying pathomechanisms remain unknown. These rare cases are referred to as ‘idiopathic angioedema’ by some authors.
Accordion: Urticaria

What is the differential diagnosis for chronic spontaneous urticaria?

International guidelines recommend that differential diagnoses be considered in all patients with signs or symptoms suggestive of chronic urticaria based on the diagnostic algorithm. These include:

What is the treatment for chronic urticaria?

There is no ‘cure’ for chronic urticaria. The goal of treatment is to achieve symptom-free control.

The approach to the management of chronic spontaneous urticaria can involve:

  • Identification and elimination of any underlying causes
  • Avoidance of any known aggravating factors, such as NSAIDs
  • Pharmacological treatment to prevent mast cell mediator release, or to prevent the effects of mast cell mediators.

Often the management for chronic inducible urticaria and chronic spontaneous urticaria will overlap.

Elimination of underlying causes

Chronic spontaneous urticaria is often reported to be associated with a variety of inflammatory or infectious diseases. Any identified infectious diseases (eg, H. pylori infection, bacterial infections of the nasopharynx, or bowel parasites) and chronic inflammatory processes (eg, gastritis, reflux oesophagitis, and inflammation of the bile duct or gallbladder) should be treated.

Plasmapheresis can reduce functional autoantibodies and has been shown to provide temporary benefit in some autoantibody-positive patients with chronic spontaneous urticaria who have not responded to any other forms of treatment.

Pharmacological treatment of chronic urticaria

About one-third of patients continue to have symptoms despite maximal tolerated daily doses of non-sedating antihistamine.

An algorithm for the symptomatic treatment of chronic urticaria is included in the international guidelines (see figure 4). The algorithm should be used with caution in children with chronic urticaria and in pregnant/lactating women as drugs contraindicated in pregnancy should not be used. Treatment should be continued until remission occurs.

Figure 4. Pharmacological treatment algorithm

Credit: Adapted from Zuberbier T, et al. Allergy 2018.


Many symptoms of urticaria are mediated by the actions of histamine on H1-receptors located on endothelial cells (causing the weals) and on sensory nerves (causing neurogenic flare and pruritus). Continuous treatment with H1-antihistamines is supported by clinical trial data. In some forms of physical urticaria, such as cold urticaria, ‘as required’ treatment may be appropriate.

Second-generation antihistamines are recommended in preference to first-generation antihistamines, as the latter have anticholinergic effects and sedative actions, and they interact with alcohol and many drugs that affect the central nervous system. Second-generation non-sedating antihistamines are the first-line symptomatic treatment for urticaria because of their good safety profiles. Those studied in the treatment of chronic urticaria include:

  • Cetirizine
  • Loratadine
  • Fexofenadine
  • Desloratadine
  • Levocetirizine
  • Rupatadine
  • Bilastine.

Terfenadine and astemizole are no longer available in New Zealand or Australia and should not be used as they are cardiotoxic in combination with ketoconazole or erythromycin.

A number of small randomised trials have confirmed the improved efficacy of higher doses of second-generation antihistamines at up to four times the recommended doses of bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, and rupatadine (some of these agents are not available and higher doses are not licensed in New Zealand or Australia). The majority of patients with urticaria who are not responding to standard doses will benefit from up-dosing of antihistamines.

Treatment of refractory chronic spontaneous urticaria

Patients with chronic spontaneous urticaria that have failed to respond to maximum-dose second-generation oral antihistamines taken for 4 weeks should be referred to a dermatologist, immunologist or medical allergy specialist.


Omalizumab is a fully human monoclonal antibody that selectively binds to free IgE, reducing the amount of IgE available in the blood and subsequently the skin. This leads to downregulation of surface IgE receptors, decreasing downstream signalling, and resulting in suppressed activation of mast cells and basophils and in reduced inflammatory responses.

Omalizumab has been shown to be effective and well-tolerated in the treatment of chronic spontaneous urticaria. Phase III studies have demonstrated efficacy at doses from 150 mg to 300 mg every 4 weeks independent of total serum IgE levels or body weight. Omalizumab improves angioedema, improves quality of life, is suitable for long-term use, and treats relapse after discontinuation.

The recommended dose for the treatment of chronic spontaneous urticaria is 300 mg by subcutaneous injection every 4 weeks. Some patients may achieve control of their symptoms with a dose of 150 mg every 4 weeks.

Omalizumab is indicated in New Zealand and Australia for adults and adolescents (≥ 12 years of age) with chronic spontaneous urticaria who remain symptomatic despite H1-antihistamine treatment. As of August 2018, it is currently listed on the Pharmaceutical Benefits Scheme in Australia for patients with severe chronic spontaneous urticaria provided specific criteria are met. Omalizumab is funded for use in chronic spontaneous urticaria in New Zealand under Special Authority criteria (refer to PHARMAC for details).


Ciclosporin is a calcineurin inhibitor and has a moderate direct effect on mast cell mediator release. The efficacy of ciclosporin in combination with a second-generation H1-antihistamine has been shown in placebo-controlled trials in chronic spontaneous urticaria. It is not recommended as a standard treatment due to the risk of significant adverse effects. Ciclosporin should be reserved for patients with severe refractory chronic spontaneous urticaria.


  • Systemic corticosteroids have not been studied in randomised controlled trials and evidence for their use in chronic urticaria is limited.
  • Long-term use of systemic corticosteroids should be avoided as high doses are often required to reduce the symptoms of urticaria with associated potentially serious adverse effects.
  • A short course of systemic steroids may be considered for severe exacerbations of chronic urticaria.

Other treatments

Other agents have been used off-label for the treatment of chronic spontaneous urticaria but have little evidence to support them. These treatments include:

These treatments may be of value to individual patients in particular clinical situations.

What is the outcome for chronic spontaneous urticaria?

Chronic spontaneous urticaria has a high rate of remission; this rate of remission was up to 80% in 12 months in one population study. However, symptoms were reported to last for longer than 1 year in up to 20% of patients and for more than 5 years in 11.3% of patients in another study.



  1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018; 73: 1392–1414. DOI: 10.1111/all.13397. PubMed
  2. CSU Working Party, Australasian Society of Clinical Immunology and Allergy (ASCIA). Chronic spontaneous urticaria (CSU) guideline. 2020. Available at: (accessed 15 May 2018).
  3. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011; 66: 317–30. DOI: 10.1111/j.1398-9995.2010.02496.x. PubMed
  4. Gaig P, Olona M, Muñoz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004; 14: 214–20. DOI: 10.1111/j.1398-9995.2010.02496.x. PubMed
  5. World Allergy Organization. Urticaria and angioedema: Global overview. 2017. Available at: [accessed 23 May 2018].
  6. Greaves MW. Chronic urticaria in childhood. Allergy 2000; 55: 309–20. DOI: 10.1034/j.1398-9995.2000.00116.x. Journal
  7. Zitelli KB, Cordoro KM. Evidence-based evaluation and management of chronic urticaria in children. Pediatr Dermatol 2011; 28: 629–39. DOI: 10.1111/j.1525-1470.2011.01518.x. PubMed
  8. Kaplan AP. Chronic urticaria and angioedema. N Engl J Med 2002; 346: 175–9. DOI: 10.1056/NEJMcp0111186. Journal
  9. Doong JC, Chichester K, Oliver ET, Schwartz LB, Saini SS. Chronic idiopathic urticaria: systemic complaints and their relationship with disease and immune measures. J Allergy Clin Immunol Pract 2017; 5: 1314–18. DOI: 10.1016/j.jaip.2016.11.037. PubMed
  10. Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014; 133: 1365–72.e6. DOI: 10.1016/j.jaci.2013.12.1076. PubMed
  11. Weller KG, Magerl M, Tohme M, et al. Development, validation and initial results of the Angioedema Activity Score. Allergy 2013; 68: 1185–92. DOI: 10.1111/all.12209. PubMed
  12. Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). Allergy 2005; 60: 1073–8. DOI: 10.1111/j.1398-9995.2005.00833.x. PubMed
  13. Weller K, Groffik A, Magerl M, et al. Development and construct validation of the Angioedema Quality of Life Questionnaire. Allergy 2012; 67: 1289–98. DOI: 10.1111/all.12007. PubMed
  14. Kolkhir P, Metz M, Altrichter S, Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy 2017; 72: 1440–60. DOI: 10.1111/all.13182. PubMed
  15. Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy 2017; 72: 2005–16. DOI: 10.1111/all.13209. PubMed
  16. Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias — the EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy 2016; 71: 780–802. DOI: 10.1111/all.12884. PubMed
  17. Novartis. Xolair (omalizumab) product information. March 2017.
  18. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128: 567–73. DOI: 10.1016/j.jaci.2011.06.010. PubMed
  19. Saini SS, Bindsley-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized placebo-controlled study. J Invest Dermatol 2015; 135: 67–75. DOI: 10.1038/jid.2014.306. PubMed
  20. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368: 924–35. DOI: 10.1056/NEJMoa1215372. Journal
  21. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013; 132: 101–9. DOI: 10.1016/j.jaci.2013.05.013. PubMed
  22. Staubach P, Metz M, Chapman-Rothe N, et al. Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy 2016; 71: 1135–44. DOI: 10.1111/all.12870. PubMed
  23. Maurer M, Sofen H, Ortiz B, Kianifard F, Gabriel S, Bernstein JA. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol 2017; 31: 1056–63. DOI: 10.1111/jdv.14075. PubMed
  24. Finlay AY, Kaplan AP, Beck LA, et al. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 2017; 31: 1715–21. DOI: 10.1111/jdv.14384. PubMed
  25. Maurer M, Kaplan A, Rosén K, et al. The XTEND-CIU study: long term use of omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol 2017; 141: 1138–39. DOI: 10.1016/j.jaci.2017.10.018. Journal
  26. Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol 2014; 150: 288–90. DOI: 10.1001/jamadermatol.2013.8705. PubMed
  27. Schedule of Pharmaceutical Benefits. Pharmaceutical Benefits Scheme (PBS). July 2018. Available at: (accessed July 2018)
  28. PHARMAC. Omalizumab. Available at: (accessed July 2018).
  29. Antia C, Baquerizo K, Korman A, Alikhan A, Bernstein JA. Urticaria: A comprehensive review: Treatment of chronic urticaria, special populations, and disease outcomes. J Am Acad Dermatol. 2018; 79: 617–33. DOI: 10.1016/j.jaad.2018.01.023. Review. PubMed

On DermNet

Other websites

Books about skin diseases


Related information

Sign up to the newsletter